Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-2011 + AD-2012
- Development stage
- Unknown
- Lead developer
- Addpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AD-2011 + AD-2012 is an investigational fixed-dose combination of two experimental drugs, designated as "AD-2011" and "AD-2012." This combination has been studied for its pharmacokinetic interaction, safety, and tolerability in healthy male volunteers. The primary indications under investigation are hypertension and hyperlipidemia. The study was sponsored by Addpharma Inc., but the specific molecular identities or mechanisms of action for either component (AD-2011 or AD-2012) have not been disclosed in public sources. The clinical trial evaluated the effects of co-administration compared to single administration of each drug[1].
Beyond the preview
Go deeper on AD-2011 + AD-2012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-2011 + AD-2012.